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ABSTRACT
MS (multiple sclerosis) is a chronic autoimmune and
neurodegenerative pathology of the CNS (central nervous
system) affecting approx. 2.5 million people worldwide.
Current and emerging DMDs (disease-modifying drugs)
predominantly target the immune system. These thera-
peutic agents slow progression and reduce severity at early
stages of MS, but show little activity on the neurodegen-
erative component of the disease. As the latter determines
permanent disability, there is a critical need to pursue alter-
native modalities. VIP (vasoactive intestinal peptide) and
PACAP (pituitary adenylate cyclase-activating peptide) have
potent anti-inflammatory and neuroprotective actions,
and have shown significant activity in animal inflammatory
diseasemodelsincludingtheEAE(experimentalautoimmune
encephalomyelitis) MS model. Thus, their receptors have
become candidate targets for inflammatory diseases. Here,
we will discuss the immunomodulatory and neuroprotective
actions of VIP and PACAP and their signalling pathways, and
then extensively review the structure–activity relationship
data and biophysical interaction studies of these peptides
with their cognate receptors.
Key words: autoimmunity, drug-design, experimental
autoimmune encephalomyelitis (EAE), neuroprotection,
PACAP, VIP.
INTRODUCTION
MS (multiple sclerosis) is a chronic autoimmune demyelinat-
ing and neurodegenerative disorder of the CNS (central
nervous system), afflicting over two-and-a-half million
people worldwide, with women affected three times more
frequently than men. MS is characterized by an extensive
and complex immune response, demyelination, glial scarring
(sclerosis), perivascular leucocyte infiltration, and oligoden-
drocyte and axonal loss (Peterson and Fujinami, 2007). Being
the most common cause of neurological disability in young
adults, it represents a prototypic autoimmune inflammatory
disorder of the CNS. Although the agent(s) that initiate
disease onset have not been clearly elucidated, several lines of
evidence, derived from the EAE (experimental autoimmune
encephalomyelitis) model, support that the disease is
autoimmune in nature, regulated by APCs (antigen-presenting
cells) and auto-reactive Th1 and Th17 cells (Steinman, 2001;
Sospedra and Martin, 2005; Korn et al., 2009). These cell types
co-ordinate the production of inflammatory cytokines and
chemokines within the CNS parenchyma, leading to the
recruitment of macrophages, mast cells, neutrophils, CD8
+ T-
cells and B-cells, whichsubsequentlyattackcomponents ofthe
CNS, including the myelin sheath and axons (Siatskas and
Bernard, 2009). The accumulation of axonal damage leads to
a permanent loss of neurological function (Lassmann et al.,
2007).
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immune response, strategies for the treatment of MS have
focusedonsuppressinginflammation,resultinginanemergence
of DMDs (disease-modifying drugs). As reviewed in Barten et al.
(2010) and Farrell and Giovannoni (2010), four approved DMDs
are currently available which target the immune system. They
include recombinant IFNb1a (interferon b1a), IFNb1b (The IFNB
Multiple Sclerosis Study Group, 1993; Jacobs et al., 1996;
PRISMS Study Group, 1998) and glatiramer acetate (Ge et al.,
2000; Comi et al., 2001; Filippi et al., 2001) as first-line
treatments, with mitoxantrone (Edan et al., 1997; Hartung et al.,
2002; Le Page et al., 2008) reserved as a second-line therapy due
to its association with cardiomyopathy, leukaemia, leucopenia,
and infection (Barten et al. 2010; Farrell and Giovannoni 2010).
Unfortunately, the efficacy of the DMDs appears to be modest.
Indeed, they are able to delay MS relapse and slow disease
progression for RRMS (relapsing-remitting multiple sclerosis),
but fail to show significant benefit in progressive forms of MS
such as SPMS (secondary progressive form of MS) and PPMS
(primary progressive form of MS) (Goodin et al., 2002; Sorensen
et al., 2005; Miller and Leary, 2007).
Currently, only injectable drugs are available for the
treatment of MS. Therefore emerging oral therapies for MS
are an especially attractive alternative to current DMDs. As
they do not rely on injections, they are convenient in use,
hence the hope for a much better compliance. Thus, much
attention has centred around four emerging oral formulations,
cladribine, laquinimod, fingolimod and dalfampridine (Fox,
2010; Losy and Kalinowska-Lyszczarz, 2011). These have
demonstrated impressive efficacy in terms of clinical outcomes
(Polman et al., 2005; Kappos et al., 2006, 2010; Fox, 2010;
Giovannoni et al. 2010; Losy and Kalinowska-Lyszczarz, 2011).
Interestingly, unlike the other agents, the mechanism of action
of dalfampridine which is a selective potassium channel blocker,
does not rely on immunomodulation but rather on restoring
the conduction of injured axons (Judge and Bever, 2006). Thus,
dalfampridine is indicated as a symptomatic therapy to improve
walking in MS patients (Judge and Bever, 2006; Goodman et al.,
2009), but is not necessarily efficacious in other domains of MS.
However, as reviewed in Losy and Kalinowska-Lyszczarz (2011)
and in Fox (2010), there are a multitude of tolerable and/or
serious adverse effects associated with each of these drugs. At
present, laquinimod and fingolimod have received fast-track
review status from the FDA (Food and Drug Administration);
they may reach the market in late 2011. In contrast, cladribine
and dalfampridine are still in the FDA’s approval review for MS.
Based on their side effect profiles and the unknown long-term
safety outcomes, it remains to be seen whether these emerging
DMDs will allow them to displace existing first-line therapies.
Although these current and emerging drugs provide benefit
for MS, especially in the early phases of the disease, existing
drugs have little effect on the neurodegenerative component
that occurs at a secondary stage of the disease. Thus, the
development of effective therapy for slowing down the course of
SPMS and PPMS has been and remains challenging. Stem cell
therapy has shown some benefit, but this therapy is still
investigational and controversial. For example, due to their
potent immune regulatory, neuroprotective properties, and
capability to home to inflammatory or injured sites (Fox et al.,
2007; Karp et al., 2009), MSCs (mesenchymal stem cells) have
recently emerged as a promising alternative for the treatment of
MS (reviewed in Siatskas et al., 2010). The therapeutic efficacy of
MSCs has also been established in EAE. Systemic transplantation
of autologous or allogeneic MSCs in relapsing remitting (Gerdoni
et al., 2007) or chronic progressive models of EAE (Zappia et al.,
2005) has shown that MSCs are efficacious in suppressing clinical
EAE disease in the early stages of disease onset, limiting the
number of CNS inflammatory lesions, reducing axonal loss and
preserving myelin structure (Zappia et al., 2005; Gerdoni et al.,
2007). Despite these positive outcomes, solid data regarding the
safety of MSCs in MS are still lacking. In addition, because of
their ability to suppress immune responses, adverse effects such
as immune deficiency leading to infection, activation of
tumour growthandmetastasismustberuledout(Djouadetal.,
2003; Karnoub et al., 2007; Wang et al., 2009).
While having moderate success in slowing the progres-
sion of disability as well as reducing the severity and frequency
of exacerbations of MS, the fact remains that these treatment
modalities do not cure the disease. As such, the need for
innovative approaches becomes of paramount importance.
In this respect, VIP (vasoactive intestinal peptide) and PACAP
(pituitary adenylate cyclase-activating peptide), two highly
homologous neuroprotective peptides initially characterized as
neuropeptide neurotransmitters, have recently been found to
show pronounced anti-inflammatory actions when administered
systemically in animal models of inflammatory disease, including
EAE (Abad et al., 2001, 2003; Delgado et al., 2001; Kato et al.,
2004; Gonzalez-Rey et al., 2006b). The immunosuppressive
effects of these peptides have, in the past, been attributed to
their capacities to modulate macrophage and DC (dendritic cell)
function and to inhibit antigen-specific Th1-driven responses
(Delgado et al., 2004b). While these mechanisms may be relevant
in EAE and other inflammatory diseases, other evidence as well
as our data indicate that these peptides may modulate the
production and/or activities of Treg (regulatory T) and Th17 cells
(Chorny et al., 2005; Juarranz et al., 2005; Fernandez-Martin
et al., 2006). Thus, because VIP and PACAP are potent anti-
inflammatory factors and because their receptors are widely
distributed in the immune system, VIP and PACAP have recently
emerged as candidates for the treatment of MS as well as other
inflammatory diseases. In this review, we will concentrate our
discussion on VIP, PACAP and their receptors and provide an
overview of what it is currently known and accepted concerning
the structure of both peptides and their respective targets, the
signalling pathways involved and their biological functions with
a focus on the immunomodulatory and neuroprotective actions.
Finally to guide investigators towards drug design and new
therapeutic pathways that can be exploited in MS and other
inflammatory diseases, we will describe structure–activity rela-
tionship data and biophysical studies that probe the interaction
between VIP/PACAP and their cognate receptors at the molecular
level.
Y.-V. Tan and J. A. Waschek
196 E 2011 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.VIP AND PACAP BACKGROUND
Isolated in porcine duodenum by Said and Mutt (1970), VIP is
a neuropeptide of 28 amino acids. Almost 20 years later,
PACAP was isolated from ovine hypothalamus extracts on the
basis of its ability to stimulate the production of cAMP in
cultured pituitary cells (Miyata et al., 1989). Furthermore,
PACAP exists in two forms as PACAP38 (38 amino acid
residues) and PACAP27 that corresponds to the N-terminal 27
residues of PACAP38 (Miyata et al., 1989, 1990). Both forms
were found to be generally equipotent in receptor binding
and AC (adenylate cyclase) assays in some cells (Buscail et al.,
1990; Miyata et al., 1990). VIP and PACAP exhibit very high
similarity with 68% sequence identity and belong to the
secretin/VIP peptide family as discussed below in more detail
in the section titled ‘Structural and functional properties’.
VIP and PACAP actions are mediated through hetero-
trimeric GPCRs (G-protein-coupled receptors). Three VIP/
PACAP receptor genes have been cloned (Laburthe et al.,
2007; Dickson and Finlayson, 2009; Vaudry et al., 2009). The
VIPR1 and VIPR2 genes encode receptors that respond equally
to VIP and PACAP named VPAC1 and VPAC2 respectively
(Ishihara et al., 1992; Lutz et al., 1993; Sreedharan et al.,
1993; Couvineau et al., 1994), whereas the ADCYAP1R gene
encodes the PACAP-preferring receptor PAC1 (Hashimoto
et al., 1993; Hosoya et al., 1993; Pisegna and Wank, 1993).
In mammals, both peptides are widely expressed in the
central and peripheral nervous systems (Pozo and Delgado,
2004; Laburthe et al., 2007; Dickson and Finlayson, 2009;
Vaudry et al., 2009), are also produced within immune cells
where they play the role of a ‘cytokine-like peptide’ (Gomariz
et al., 2001; Delgado et al., 2004b), and are induced in both
neuronsandimmunecells duringinflammation(Gomarizet al.,
1993; Gaytan et al., 1994; Leceta et al., 1996; Zhang et al., 1998;
Vassiliou et al., 2001; Abad et al., 2002; Armstrong et al., 2004;
Delgado et al., 2004b; Laburthe et al., 2007; Vaudry et al., 2009).
Likewise, their receptors are mainly distributed in the nervous,
endocrine and immune systems (Delgado et al., 2004b; Laburthe
et al., 2007; Vaudry et al., 2009). In consonance with this large
distribution, they are pleiotropic neuropeptides involved in
many physiological and pathophysiological processes (Vaudry
et al., 2009) and will be discussed in particular with respect to
MS-relevant actions in the ‘Potent immunomodulatory actions
of VIP and PACAP’ section.
STRUCTURAL AND FUNCTIONAL PROPERTIES
VIP and PACAP
VIP and PACAP belong to the amidated VIP/secretin family
that adopts common properties: (i) a length of 27–44 amino
acid residues, (ii) an a-helical configuration along the
sequence from residue 6 to the C-terminal end of the
peptide, and a non-structured N-terminal end (Gronenborn
et al., 1987; Romier et al., 1993; Thornton and Gorenstein,
1994; Pellegrini et al., 1998; Inooka et al., 2001; Tan et al.,
2006) and (iii) the presence of a common N-terminal structural
motif, named N-cap (Neumann et al., 2008). Utilizing CD
spectroscopy and/or NMR spectroscopy, it has been reported
that most of the VIP-28 amino acid sequences have an a-
helical structure (sequence 7–28) with the exception of the
N-terminal 1–5 sequence that has no defined structure in
solution when unbound to the receptor (Tan et al., 2006)
(Figure 1), whereas PACAP27 peptide is characterized by a
disordered N-terminal domain consisting of eight amino
acids, followed by an a-helical structure (Inooka et al., 2001;
Bourgault et al., 2009b). In addition, the conformation of
PACAP38 mirrors that of PACAP27 with the C-terminal 28–38
short helix connected by a flexible hinge to the 1–27 region
(Wray et al., 1993). Furthermore, it is also widely agreed that
the disorganized N-terminal 1–5 segment plays a crucial role
in activation of AC (Laburthe et al., 2007; Vaudry et al., 2009).
Particularly, the N-cap motif was suggested to be involved in
receptor activation and may possibly be used for the design of
drugstargeting VPAC receptorsandothermembersoftheclass
B GPCRs (Neumann et al., 2008), while the a-helical con-
formation is mainly involved in the peptide binding and
receptor specificity (Laburthe et al., 2007; Vaudry et al., 2009).
Figure 1 A 3-D ribbon representation of VIP interaction with the VPAC1
N-terminal domain
The VPAC1 receptor N-terminal domain encompassing sequence 44–137 is
shown in light grey. The structure reveals a Sushi domain characterized by
two anti-parallel b-sheets named b1, b2, b3a n db4. Most of the VIP-28
sequence, which is shown in middle grey, has an a-helical structure
(sequence 7–28). Photoaffinity labelling experiments showed that Asp
107,
Gly
116, Cys
122, Lys
127 and sequence 129–137 that connects the N
ter domain
and the first helical TM (shown in dark grey) in the N-terminal domain are
physically in contact with the side chains of Phe
6, Tyr
22,A s n
24,A s n
28 and
Phe
0 (shown in dark grey) of VIP respectively. Reprinted from Neuropeptides,
44, A. Couvineau, E. Ceraudo, Y.-V. Tan and M. Laburthe, VPAC1 receptor
binding site: contribution of photoaffinity labeling approach, 127–132, E
2010, with permission from Elsevier.
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Approx. 20 years ago, VIP and PACAP receptors were design-
ated as VPAC1, VPAC2 and PAC1 receptors by the International
Union of Pharmacology according to their relative affinity for
their ligands, PACAP and VIP (Harmar et al., 1998). With the
cloning of many other receptors for peptides of the secretin
family, a new GPCR subfamily was born and named class B
GPCR or class II GPCR or also ‘secretin-like’ receptor family
(Laburthe et al., 2007; Vaudry et al., 2009). Subfamily B GPCRs
exhibit 25–50% amino acid identity among themselves and
low primary sequence homology with other GPCR classes, but
display a common seven TM (transmembrane) helical config-
uration denoted as TM I to TM VII, which are interconnected
by extracellular and intracellular loops (Hosoya et al., 1993;
Pisegna and Wank, 1993; Sreedharan et al., 1993; Usdin et al.,
1994; Laburthe et al., 2007; Dickson and Finlayson, 2009;
Vaudry et al., 2009). In addition, they exhibit specific features:
(i) a relatively large (.120 residues) N-terminal domain (N
ter
domain), which is usually smaller in the class A GPCRs or
Rhodopsin-like receptors, (ii) six highly conserved cysteine
residues forming three disulfide bridges that structure the N
ter
domain, (iii) the presence of a signal peptide probably involved
in addressing the receptor towards the plasma membrane,
(iv)severalconservedglycosylationsiteswithintheN
terdomain
involved in receptor trafficking, (v) the absence of archetypical
A subfamily GPCR motifs such as E/D-R-Y or NP-xx(x)-Y and
(vi) a common but complex gene organization (Laburthe et al.,
1996, 2007).
Molecular anatomy of VIP–PACAP interaction
with their receptors
To dissect the binding mechanism between VIP/PACAP
and their receptors and particularly to define the residues
and structural elements involved, numerous structure–activity
relationship experiments have been conducted. These have
included chemical modifications, amino acid substitutions,
deletion mutagenesis, molecular chimaerisms and photoaffi-
nity labelling analyses as reviewed in Laburthe et al. (2007),
Vaudry et al. (2009) and Couvineau et al. (2010). Interestingly,
the data indicate that the N
ter domain of the VIP and PACAP
receptors is a major binding site, essential for the recognition of
their respective ligands (Cao et al., 1998; Laburthe et al., 2007;
Vaudry et al., 2009; Couvineau et al., 2010; Dejda et al., 2011).
Due to its quite recent recognition, no 3-D structure of a B family
receptor is yet available unlike some class A GPCRs. However,
the N-terminal domain structures of five type B receptors
including human PAC1 receptor (Sun et al., 2007a) have been
determined by NMR spectroscopy or X-ray crystallography. The
structures revealed a Sushi domain characterized by two anti-
parallel b-sheets (named b1, b2, b3 and b4), and stabilized by
three disulfide bonds between six highly conserved cysteine
residues and by a putative salt bridge involving acidic and
basic residues (Grace et al., 2004). This Sushi domain has been
shown to play a crucial role in peptide ligand binding (Grace
et al., 2004). Recently, the development of a structural model
of VPAC1 N-terminal domain indicated a structure similar to
that of a Sushi domain (Tan et al., 2006) (Figure 1).
A detailed molecular description of the interaction of VIP
with one of its receptors, VPAC1 receptor, has recently been
provided by performing extensive photoaffinity studies (Tan
et al., 2003, 2004, 2006; Ceraudo et al., 2008a) in which the
full-length ligand is covalently bound to its native receptor.
This has allowed: (i) analyses of point-to-point interactions
between the peptide and its target protein and (ii) the
accurate determination of a spatial view of the ligand
within the binding site of the receptor. For example, the
residues in positions 6, 22, 24 and 28 within the VIP sequence
were replaced by a photoreactive Bz-Phe (benzophenone-
Phe) amino acid. As illustrated in Figure 1, these studies hence
demonstrated that side chains in positions 6, 22, 24 and 28
of VIP are in direct contact with different amino acids in the
N
ter domain of the receptor e.g. Asp
107, Gly
116, Cys
122 and
Lys
127 respectively (Tan et al., 2003, 2004, 2006; Ceraudo et al.,
2008a). Based on the four physical interaction sites, identified
by the photoaffinity strategy, to the NMR structure of VIP, and
the structural model of the VPAC1 N
ter domain, the structure
of VIP has been docked in the VPAC1 N
ter domain. This docking
created an accurate 3-D structural model in which the C-terminal
segment of the N
ter domain of the receptor accommodates the
VIP molecule, at least for the 6–28 sequence (Tan et al., 2003,
2004, 2006; Ceraudo et al., 2008a) (Figure 1). In parallel, under
molecular dynamic simulations in water for over 14 ns, this
model exhibited a remarkable stability (Ceraudo et al., 2008a).
A ‘two-site’ binding model
The model described above may realistically illustrate the
binding between VIP and VPAC1, and potentially explains how
the receptor is activated. It is in agreement with the currently
accepted concept of a ‘two-site’ binding model for the
interaction of natural ligands to family B GPCRs (Hoare, 2005).
In this model, the central and C-terminal a-helical segments of
the ligand are trapped by the N
ter domain of the receptor. This
step positions the disordered N-terminal region of the peptide
ligandforitsinteractionwiththeTMdomainofthereceptorto
initiate intracellular signalling (Hoare, 2005). In this respect,
the integrity of the a-helical conformation seems crucial
f o rt h eb i n d i n go fV I Pa n dP A C A Pt ot h e i rr e c e p t o r s .A c c o r d i n g l y ,
deletionintheC-terminaldomainofPACAPreducesdrastically
the binding affinity without altering the propensity of the
analogues to activate the receptor at high concentration
(Bourgault et al., 2008b). Conversely, modifications of the dis-
ordered N-terminal portion of PACAP molecule decrease the
biological activity ofthepeptide (Onoue et al., 2001;Bourgault
et al., 2009b). In fact, deletion of the entire N-terminal
segment, i.e. PACAP(6–38) leads to a potent PAC1/VPAC2
antagonist (Vandermeers et al., 1992). It seems clear that the
presence of an N-capping signature in the N-terminal end of
VIP, PACAP and other members of the VIP/secretin family may
contribute to position His
1 of these peptides into their cognate
receptors, triggering the release of the Gas subunit from the
Y.-V. Tan and J. A. Waschek
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et al., 2008). Recently, in order to attempt to identify the
molecular determinants of VPAC1 involved in the recognition
of VIP’s N-terminal part, photoaffinity labelling experiments
have been carried out with a new VIP photoreactive probe
containing a Bz-Phe in position 0 (Ceraudo et al., 2008b).
The results revealed that the VIP N-terminal part physically
interacts with the receptor domain connecting the N
terdomain
and the first TM helix (Ceraudo et al., 2008b) (Figure 1).
Although numerous structure–activity studies and photo-
affinity labelling experiments have provided interesting
insights to understand the molecular interactions between
VIP/PACAP peptides and their receptors, the determination of
the structure of the full-length VIP/PACAP receptors clearly
remains a major challenge for all investigators in the field,
and will facilitate the emergence of new potent drugs.
SIGNALLING PATHWAYS
As discussed earlier, two of the receptors, VPAC1 and VPAC2,
recognize PACAP and the related peptide VIP with equally
high affinity. The third, PAC1, is a PACAP-preferring receptor.
Due to alternative splicing, different PAC1 variants exist and
mediate differential coupling to second messengers. Indeed,
five variants resulting from alternative splicing in the third
intracellular loop region have been identified in rat (Spengler
et al., 1993). These variants are characterized by the absence
(short variant, S) or presence of either one or two cassettes of
28 amino acids (hip or hop1 variant) or 27 amino acids (hop2
variant) (Spengler et al., 1993). Furthermore, the presence of
the hip cassette impairs AC stimulation and abolishes PLC
(phospholipase C) activation. In addition, a very short splice
variant of PAC1, characterized by a 21-amino acid deletion in
the N-terminal extracellular domain showed altered selectiv-
ities for PACAP38 and PACAP27 isoforms (Dautzenberg et al.,
1999). Another PACAP receptor variant termed as PAC1 TM4
(transmembrane domain 4) has been cloned in the rat cerebellum
(Chatterjee et al., 1996).
Each of these GPCRs is typically coupled via the hetero-
trimeric Gs-protein (Gas) to AC, cAMP production and the PKA
(protein kinase A) pathway activation (Laburthe et al., 2007;
Dickson and Finlayson, 2009; Vaudry et al., 2009). However,
they can couple to other intracellular messenger systems in
some cells in parallel or downstream of cAMP including path-
ways such as nitric oxide (Murthy et al., 1993), Gaqo rG ai/PLC
leading to an increase in the intracellular calcium concentration
([Ca
2+]i) and the PKC (protein kinase C) signalling stimulation
(Spengler et al., 1993; Dickson and Finlayson, 2009), PI3K
(phosphatidylinositol 3-kinase; Straub and Sharp, 1996), src
(Koh, 1991), MAPKs (mitogen-activated protein kinases; Barrie
et al., 1997; Villalba et al., 1997; Lelievre et al., 1998), Jak/STAT
(signal transducer and activator of transcription) and NF-kB
(nuclear factor kB; Delgado and Ganea 1999, 2000). Consistent
with their diverse biological actions, VIP and PACAP receptor
signalling cascades include a constellation of second messen-
gers that are likely dependent not only on the receptor and
G-proteins but also on the repertoire of accessory molecules.
Thus, besides their interaction with G-proteins, recent results
showed that VIP and PACAP receptors were also able to interact
with non-G proteins or ‘accessory proteins’ and to transduce
signals independently of the G proteins (Sun et al., 2007b). The
‘accessory protein’ group is known to modulate the overall
function of the receptors, as extensively demonstrated for the A
GPCR subfamily (Bockaert et al., 2004), but poorly documented
for the subfamily B GPCRs. For example, a recent report clearly
indicated that VPAC1 but not VPAC2 hetero-dimerizes with
RAMPs (receptor-activity-modifying proteins) (Christopoulos
et al., 2003; Sexton et al., 2009). Particularly, by interacting
with RAMP2, VPAC1 induces inositol triphosphate production
and increases intracellular calcium without affecting the
coupling to AC (Christopoulos et al., 2003). Recently, the PDZ
domainof S-SCAM (synapticscaffolding molecule)wasfoundin
the VPAC1 receptor C-tail, implying its potential recruitment by
S-SCAM to synaptic buds (Gee et al., 2009). The latter was
reported to result in inhibition of VIP-induced cAMP production
and inhibition of agonist-induced internalization of VPAC1 (Gee
et al., 2009). Besides the role of RAMPs and/or S-SCAM inter-
action with VPAC1 receptors, one report describes the possible
interaction between CaM (calmodulin) and this receptor
although the functional role of this interaction remains unclear
(Mahon and Shimada, 2005). Finally, it should be noted that
VPAC1 receptor is able to homo-dimerize and hetero-dimerize
with VPAC2 or secretin receptors (Harikumar et al., 2006),
although again the functional signification remains unclear.
POTENT IMMUNOMODULATORY ACTIONS OF
VIP AND PACAP
VIP, PACAP and their receptors are broadly expressed in the
CNS and in most peripheral organs. Given this fact, it is not
surprising that these peptides elicit pleiotropic physiological
effects (Delgado et al., 2004b; Laburthe et al., 2007; Vaudry
et al., 2009). Early reports suggested that VIP and PACAP exerted
a multitude of effects on CNS, cardiovascular, circulatory and
respiratory systems and on metabolic function (Said et al., 1970;
McCulloch and Edvinsson, 1980; Miyata et al., 1989, 1990).
Moreover, both peptides have been proposed for the treatment
of asthma (Groneberg etal.,2001), impotence (Kalsi etal., 2002),
treatment of septic shock (Delgado et al., 1999b, 2004b;
Martinez et al., 2002, 2005) and diabetes (Nakata and Yada,
2007). More recent studies also point to a plethora of putative
growth factor-like actions impacting on development and
regeneration (Gozes and Brenneman, 2000; Dejda et al., 2005;
Shioda et al., 2006) and cancer pathogenesis (Moody, 1996;
Moody et al., 2003). In the following section, we focus on the
immunomodulatory actions of VIP and PACAP (Gomariz et al.,
VIP and PACAP receptors in multiple sclerosis
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1992001; Delgado et al., 2004b; Pozo and Delgado, 2004;
Gonzalez-Rey et al., 2007). Growth factor-like actions of these
peptides are discussed in a subsequent section.
Macrophage function (reviewed in Delgado et al.,
2004b)
Macrophages constitute a major source of chemokines and
pro-inflammatory molecules implicated in inflammatory
responses and constitute a high percentage of the migrating
cells to inflamed tissues. They constitutively express VPAC1
and PAC1, and when exposed to inflammatory stimulus
express VPAC2. The effect of VIP and PACAP on macrophage
function has been repeatedly demonstrated. In unstimulated
macrophages, VIP and PACAP increase IL-6 (interleukin 6)
production through activation of the PKA and PKC pathways
(Martinez et al., 1998a, 1998b). In contrast, it was reported
that they inhibited the production of pro-inflammatory TNFa
(tumour necrosis factor a), IL-6 and IL-12 in macrophage
cultures in response to LPS (lipopolysaccharide) (Martinez
et al., 1998a; Delgado et al., 1999d, 1999e). The negative
effectonTNFaandothermacrophage derivedpro-inflammatory
mediators (IL-12, IFNc and NO) appeared to be mediated
through the constitutively expressed VPAC1, although the
inducible expressed VPAC2 could also participate (Delgado
et al., 2000). More recently, both peptides were shown to
increase the synthesis and release of anti-inflammatory
molecules like IL-10 and the IL-1Ra (IL-1 receptor antagonist),
leading to a suppression of inflammatory responses (Delgado
et al., 1999c). Finally, it has been reported that VIP and PACAP
inhibit the production of several macrophage-derived chemo-
kines such as MIP-2 (macrophage inflammatory protein 2), KC
(keratinocyte chemoattractant) (IL-8), MIP-1a, MIP-1b, MCP-1
(monocyte chemoattractant protein 1) and RANTES (regulated
upon activation, normal T-cell expressed and secreted),
produced by LPS-activated macrophages (Delgado and
Ganea, 2001).
APC/T-cell function
T-lymphocyte differentiation is finely orchestrated by APCs
through co-stimulatory molecules and the production of
specific APC cytokines. Thus, Th cells differentiate upon antigen
presentation into four main cell subsets named Th1, Th2, Th17
and adaptive (also called inducible) regulatory T-cells (Zhu and
Paul, 2008). Interestingly, in vitro studies showed that both
neuropeptides were able to modify via VPAC1 receptors the
expression of the APC co-stimulatory molecules B7.1 and B7.2
(oralso calledCD80/CD86)(Delgadoet al.,1999a,1999f,2000).
For example, in resting macrophage cultures, VIP and PACAP
promoted B7.2, but not B7.1, expression. In contrast, both
peptides were shown to inhibit in vivo and in vitro the
expression of B7.1 and B7.2 of LPS/IFNc-activated macro-
phages (Delgado et al., 1999a, 1999f, 2000). VIP and PACAP
also appear to regulate the ability of DCs to activate T-cells
(Delgado et al., 2004c). Indeed, in BM (bone marrow)-derived
DCs, theyup-regulated,viaVPAC1,CD86 (B7.2) expression, and
enabled them to stimulate T-cell proliferation and differenti-
ation into Th2 effectors in vivo and in vitro (Delgado et al.,
2000, 2004c). In contrast, VIP/PACAP down-regulated CD80/
CD86 (B7.1/B7.2) expression in LPS-stimulated DC cells and
strongly reducedtheir capacity to stimulate T-cell proliferation
and to secrete Th1 and Th2 cytokines. More importantly,
related to these results, it has been shown that both human
and murine DCs generated in vitro in the presence of VIP
exhibited a ‘tolerogenic’ phenotype characterized as
CD11c
lowCD45RB
high with the absence of CD80, CD86 and
CD40 expression and ability to secrete high amount of the
anti-inflammatory IL-10 cytokine after LPS stimulation.
Remarkably, these VIP-induced tolerogenic DCs promoted the
generation of Treg cells in vivo and in vitro (Delgado et al.,
2005; Gonzalez-Rey et al., 2006a).
T-cellfunction (reviewed inDelgado etal., 2004b)
VIP/PACAP and their GPCRs also appear to play an important
role in many aspects of T-cell-dependent immunity, imper-
ative to control infectious, autoimmune diseases and organ
transplant rejection. On resting CD4
+ T-cells, VPAC1 is ex-
pressed constitutively, whereas upon activation by anti-CD3
and anti-CD28 antibodies, VPAC1 is down-regulated while
VPAC2 is induced (Lara-Marquez et al., 2001). Interestingly,
although most of the Th differentiation occurs via APC
interaction as discussed above, a few in vivo and in vitro
studies suggested that VIP and PACAP may in some cases,
promoteTh2responsesbyregulatingTh2-specifictranscription
factors, cytokine responses, proliferation, survival and chemo-
taxis (Delgado et al., 2002; Voice et al., 2004). VPAC 1 and
VPAC2receptorsmaybeinvolvedintheseactions. Forexample,
it was shown that activated CD4
+ T-cells expressed VPAC2
during differentiation to the Th2 phenotype, suggesting VPAC2 as
a modulator for Th2 phenotype. On the other hand, VIP and
PACAP via VPAC1 down-regulated in vivo and in vitro the
production of CXCL10 (CXC chemokine ligand 10; IP-10) and
up-regulated CCL22 (CC chemokine ligand 22) [MDC (macro-
phage-derived chemokine)], purported to be Th1- and
Th2-specific chemokines respectively. This might lead to the
preferential recruitment of the anti-inflammatory Th2 cell
population (Jiang et al., 2002; Delgado et al., 2004a).
VIP/PACAP effects on human T-cell function in
MS
The dynamics of VPAC receptor expression in peripheral blood
T-lymphocytes from MS patients compared with healthy
controls has been investigated (Sun et al., 2006). Similar to
what had been shown previously for mouse lymphocytes,
resting human T-cells from both MS patients and controls
expressed high levels of VPAC1, but very low levels of VPAC2.
Like in mice (Vomhof-DeKrey and Dorsam, 2008; Vomhof-
DeKrey et al., 2008), when lymphocytes from either group
were activated in vitro with anti-CD3 and anti-CD28 antibodies,
Y.-V. Tan and J. A. Waschek
200 E 2011 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.VPAC1 expression was significantly down-regulated. This
decrease in VPAC1 expression was compensated by a strong
up-regulation of the VPAC2 receptor in healthy control
lymphocytes, whereas the induction was severely impaired
in MS patients (Sun et al., 2006). Interestingly, while CD4
+
lymphocytes from healthy controls were able in the presence
of VIP, to polarize into a Th2 phenotype with increased
expression of the Th2-associated transcription factor Stat-6, this
VIP effect was significantly dampened in MS patients, which
could be due to the aberrant expression of its receptors (Sun
et al., 2006).
VIP and PACAP as therapeutic agents in EAE
(Figure 2)
Based on the substantial success of systemic administrations
of VIP and PACAP in other animal models of chronic inflam-
matory disease such as rheumatoid arthritis (Abad et al.,
2001; Delgado et al., 2001) and Crohn’s disease (Abad et al., 2003),
investigators have begun to examine whether or not these
peptides might have efficacy in the EAE model of MS. For
instance, in the earliest report, the effects of PACAP on MOG35–55
(myelin oligodendrocyte glycoprotein 35–55)-induced EAE were
examined in C57BL/6 mice (Kato et al., 2004). Intraperitoneal
administration of PACAP every other day after immunization
with MOG ameliorated both the clinical and pathological
manifestations of EAE. Splenocyte cultures from mice treated
with PACAP exhibited significantly reduced MOG-specific
Th1 IFNc production. In vitro analysis revealed that PACAP
suppressed the production of inflammatory cytokines, includ-
ingTNFa,IL-1band IL-12,andexpressionoftheco-stimulatory
factor B7.2 on macrophages and microglia. The authors sug-
gested that PACAP suppressed induction of EAE primarily via
suppression of APC function and inflammatory cytokine produc-
tion. Other work focused on the therapeutic action of VIP in EAE.
In these studies, the clinical and pathological scores in chronic
MOG35-55-induced EAE in C57BL/6 mice were dramatically
reduced by a 3-day treatment with VIP begun before or after
the onset of EAE (Gonzalez-Rey et al., 2006b). Three-day treat-
ment with either VIP or PACAP was also found to ameliorate
EAE in a relapsing-remitting model (PLP139-151-induced
SJL/J mice), with a blockade of symptoms lasting 60 days.
The reduction of EAE and decreased inflammation after VIP
administration was associated with decreased spinalcord levels
of pro-inflammatory cytokines (TNFa, IL-6, IL-1b, IL-18 and
IL-12), enzymes [iNOS (inducible nitric oxide synthase)],
Figure 2 Potential effects of VIP and PACAP in EAE, a mouse MS model
This is a schematic representation of the EAE-mediated immune response with a focus on APCs and T-cells. Briefly, after EAE
induction, APCs present in the periphery of the MOG antigen to Th progenitors (Thp) which subsequently differentiate into Th1 or
Th17 cell subsets. T effector Th1 and Th17 cells, so-called encephalitogenic Th cells, migrate towards the CNS crossing the
blood2brain barrier (BBB). In the CNS, once re-activated by microglia/APC cells, Th1 and Th17 cells proliferate and secrete IFN-c
and IL-17 respectively, mounting a robust pro-inflammatory immune response against endogenous myelin that involves the secretion
of multiple pro-inflammatory cytokines and chemokines. This leads to the recruitment of increasing numbers of immune cells, which
amplifies the pro-inflammatory response. Ultimately, demyelination and neurodegeneration events occur, leading to the
development of EAE symptoms. Due to their potent immunomodulatory and neuroprotective functions, VIP and PACAP can
potentially act both in the periphery and the CNS to reduce and block the EAE pathogenesis. In the periphery, both peptides have
been shown to inhibit Th1 and Th17 activities, while stimulating anti-inflammatory response by favouring Th2 and Treg generation.
In the CNS, VIP and PACAP down-regulate T-cell re-activation and promote neuroprotection and neurorepair. These two phenomena
lead to the suppression of EAE symptoms.
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201chemokines (RANTES, MIP-1, MIP-2, MCP-1 and IP-10) and
CCRs (CC chemokine receptors; CCR-1, CCR-2 and CCR-5)
and increased levels of the anti-inflammatory cytokines IL-10,
IL-1Ra and TGFb (transforming growth factor b). The latter
inductions occurred despite a 4-fold reduction in the number
of inflammatory cells in the spinal cord as detected by FACS.
Lymph nodes from VIP-treated mice showed reduced antigen-
induced proliferation, and lower and higher production of Th1
and Th2 cytokine respectively.
VIP and PACAP as potential modulators of Treg
and Th17 production and activity: significance in
EAE (Figure 2)
As previously discussed, these peptides have formally been
thought to act primarily via VPAC receptors by inhibiting
macrophage activity and skewing Th1/Th2 responses in
models of autoimmune diseases. However, with the increased
interest in Treg cells in autoimmunity, and the discovery that
many autoimmune diseases seem to be driven primarily by
Th17 responses, emerging data indicated that VIP and PACAP
might regulate the production or expansion of regulatory
T-cells and Th17 responses. In the context of the EAE model,
the administration of VIP to mice resulted in the expansion
of the CD4
+CD25
+Foxp3
+ expressing T-cells (Tregs) in the
periphery and the nervous system, which were shown to
inhibit encephalitogenic T-cell activation (Fernandez-Martin
et al., 2006). VIP was also reported to enhance the suppressive
efficiency of Tregs on a per cell basis. In adoptive transfer
experiments, VIP-generated CD4
+CD25
+ Tregs were found
to transfer suppression and significantly ameliorate the
progression of the disease. Conversely, CD4
+ T-cells from
VIP-treated EAE mice did not transfer disease, whereas
CD4
+CD25
+-depleted T-cells from VIP-treated EAE mice did.
In another study, the same investigators studied potential
mechanisms by which VIP induced expansion of Tregs (Chorny
et al., 2005). In the ex vivo experiments, mice with evolving
EAE were injected with DCs generated from cultures of
syngenic BM cells in the presence or absence of VIP (cells
were termed DCVIP and DCcon respectively). Injection of DCVIP
but not DCcon was found to reduce EAE symptoms in associa-
tion with a decreased ability of draining lymph node cultures
to proliferate and produce IFNc cytokine in response to
autoantigen. Moreover, injection of DCVIP-induced MOG-
specific regulatory T-cells, but not DCcon-induced cells,
significantly attenuated EAE. These results suggest that the
induction and/or activation of regulatory T-cells via the pro-
duction of tolerogenic DCs may be a mechanism by which
exogenous VIP (or perhaps PACAP) alleviates EAE. No studies
have specifically examined the role of VIP or PACAP in Th17
cells in EAE or other inflammatory disease models, although
IL-17 gene expression was found to be reduced in VIP-treated
against untreated mice in CIA (collagen-induced arthritis;
Juarranz et al., 2005) and in colonic extracts in a chemical-
induced colitis model (Abad et al., 2005).
One of the problems that could limit the use of VIP as a
therapeutic agent in MS or other diseases is the short
biological half-life (tK) of the peptide. This latter topic will
be discussed later inthe ‘Pharmacology and drug design’ section.
In order to sustain beneficial VIP levels in the organism, the
group of Toscano et al. (2010) tested in mice a strategy based on
the transfer of DCs transduced with vectors expressing VIP
(lenti-VIP DCs). The intravenous transfer of these cells to mice
with EAE reduced the clinical symptoms of the disease as well
asthemRNA expressionofthekeypro-inflammatorycytokines
IL-1b, TNFa and IL-6. After inoculation, these cells were found
in several organs such as the liver, lung, lymph nodes and
spleen. The mechanisms for the therapeutic actions of these
cells could be double. On the one hand, before transfer, the
lenti-VIP DCs were functionally ‘tolerogenic’. On the other
hand, the serum levels of VIP in these mice assessed 48 h after
inoculation were 3-fold higher than those in non-injected
mice, demonstrating that transfer of these cells resulted in
systemic levels of VIP, leading to a more robust inhibition of
the inflammatory response.
GENETIC MANIPULATION OF VIP, PACAP AND
THEIR RECEPTORS IN MICE AND THEIR
APPLICATION TO INFLAMMATORY DISEASE
MODELS
VIP KO (knockout) and PACAP KO mice in EAE
As for many peptides and their cognate receptors, clear
insights into their physiological roles have recently been
gained through the use of genetically engineered mice. These
have been used to investigate immunomodulatory actions
of endogenous VIP and PACAP. For example, although the
mechanism is still uncertain, we showed that the severity of
MOG35–55-induced EAE is increased in PACAP-deficient mice
in association with enhanced Th1/Th17 and diminished Th2
responses in the spinal cord, indicating that endogenous
PACAP is protective in this model of autoimmune disease (Tan
et al., 2009). Moreover, we found a significant reduction in
the abundance of Tregs in the lymph nodes of PACAP KO mice
during the recovery phase of the disease. It has been exper-
imentally demonstrated in this model of EAE that natural, but
not inducible, Tregs are involved in the recovery phase (Korn
et al., 2007). Thus, the results from PACAP KO mice suggest a
new role for PACAP as an endogenous modulator of natural
Treg expansion. We also recently studied the response of VIP
KO mice to EAE induction (Abad et al., 2010). In contrast to
PACAP KO mice, VIP KO mice were highly resistant to EAE
at the clinical and histopathological levels. Supporting this
phenotype, the levels of multiple pro-inflammatory cytokines
in the spinal cord were strikingly reduced in the KO mice. The
lack of inflammatory disease in these mice precluded an
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Interestingly, ex vivo antigen-rechallenge studies suggested
that the immunization phase of EAE was unimpaired in VIP KO
mice. Moreover, immune cells isolated from MOG-immunized
VIP KO mice had encephalitogenic properties as exhibited by
the fact that they were capable of inducing EAE when
adoptively transferred to WT (wild-type) hosts. Although the
mechanism for the EAE resistance of VIP KO mice remains to
be elucidated, immune cells were found to be trapped in the
meninges of the brain and spinal cords, and failed to invade
the CNS parenchyma of VIP KO mice, suggesting a defect in
immune cell migration.
VIP/PACAP receptor KO mice in inflammatory
disease models
In addition to mice deficient in VIP or PACAP, the develop-
ment of receptor KO mice has provided valuable tools to
elucidate the mechanisms responsible for the actions of these
peptides in the immune system. Although not yet tested for
EAE susceptibility, they have been subjected to different
models of inflammatory diseases. For example, PAC1 KO mice
showed increased mortality after LPS injection in comparison
with their WT counterparts, a finding linked to an over-
stimulation of the IL-6-dependent coagulation and chemotaxis
cascades (Martinez et al., 2002, 2005). Inflammatory phenotypes
of VPAC2 receptor KO mice have also been examined. In these
mice, anti-CD3/CD28 stimulation of purified splenic CD4
+ T
resulted in 3-fold higher levels of IL-2 and IFNc than in WT
mice and 90% lower levels of IL-4 (Goetzl et al., 2001). These
results, along with a finding of relative resistance to cutaneous
anaphylaxis and an enhanced hapten-evoked cutaneous DTH
(delayed-type hypersensitivity) response in KO mice, suggested
that loss of VPAC2 leads to a state of enhanced delayed-type
hypersensitivity and depressed immediate-type hypersensitivity
(Goetzl et al.,2001).Conversely, transgenicmiceoverexpressing
VPAC2 receptors specifically in CD4
+ T-cells exhibited increased
Th2/Th1 cytokine profiles and alterations in delayed against
immediate hypersensitivity (Voice et al., 2001). The studies
reinforce the in vivo and in vitro data suggesting that PACAP
and VIP serve to promote and/or reinforce Th2-type responses
at the expense of Th1.
In vitro studies by Yadav et al. (2008) addressed the
complexity of VPAC1 and VPAC2 signalling effects in
lymphocyte differentiation. Interestingly, in vitro treatment
of isolated CD4
+ cells with VIP in the presence of TGFb
promoted the generation of T-cells with a Th17-like pheno-
type, producing IL-17 and IL-22 but not IL-21. It was inferred
that this effect was mediated by VPAC1 because this is the
main receptor expressed in resting lymphocytes. Moreover, in
CD4
+ cells from VPAC2 KO mice, where the expression of
VPAC1 is enhanced, Th17-like polarization was even stronger.
This suggests that VIP signalling through VPAC1 receptor
can, at least in some contexts, promote a potential pro-
inflammatoryT-cellphenotype.StudiesusingthemodelofDSS
(dextran sodium sulfate) colitis supported this possibility
(Yadav et al., 2011), because VPAC1 KO mice exhibited a
milder disease than WT controls, whereas VPAC2 KO mice
exhibited enhanced colitis after DSS treatment.
Therapeutic actions of VIP/PACAP in other mouse
models of inflammatory disease
VIP and PACAP have also been shown to have beneficial
therapeutic effects in mouse models of rheumatoid arthritis,
septic shock and Crohn’s Disease. CIA exhibits most of the
clinical and histological features of rheumatoid arthritis in
humans. Either VIP or PACAP, injected intraperitoneally every
day or every other day, reduced dramatically the incidence
andtheseverity ofarthritis,even whenthey were administered
in the late stages of the disease (Abad et al., 2001; Delgado
et al., 2001). After treatment, paw joints of the VIP- and
PACAP-treated animals, unlike controls, showed no evident
signs of inflammation (redness and swelling), and in the
histological study of the joint tissue there was no pannus
formation in the treated animals, and the joint structure was
preserved.Administration of VIPor PACAP was found toinhibit
both the inflammatory and theautoimmune (Th1) components
of the disease and to promote a Th2 cytokine profile. In
another model, VIP and PACAP were also found to protect
against endotoxin-induced lethality and prevent septic shock-
associatedhistopathologicalalterations(Delgadoetal.,1999b).
Finally, in a chemical-induced colitis model, VIP was found
reduce the clinical and histopathological severity, abrogating
body weight loss, diarrhoea and macroscopic and microscopic
intestinal inflammation (Abad et al., 2003). The therapeutic
effects were associated with down-regulation of both
inflammatory and Th1-driven autoimmune responses, and an
up-regulation of Th2 anti-inflammatory cytokines (Abad et al.,
2003).Thus,PACAPandVIPhaveemergedascandidatesforthe
treatment of autoimmune and other inflammatory diseases,
especially those associated with an overproduction of Th1
cytokines.
Taken together, through their actions on cytokines, chemo-
kines, cell adhesion molecules, and co-stimulatory molecules
produced or expressed by activated APCs, and through its direct
and/or indirect effects on Th cell responses, VIP and PACAP
appear as important endogenous immunomodulatory molecules
that exert mainly protective anti-inflammatory actions in many
different models of autoimmune diseases.
OTHER VIP/PACAP ACTIONS RELEVANT TO
MULTIPLE SCLEROSIS
Potent neuroprotective properties
Evidence from both in vitro and in vivo experiments described
below suggest that VIP and PACAP may promote neural cell
proliferation, survival and axon regeneration as well as
VIP and PACAP receptors in multiple sclerosis
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203oligodendrocyte progenitor proliferation and maturation.
However, despite their homologies, it is apparent that in
most cases, PACAP was shown to be significantly more potent
than VIP. The latter may be due to the fact that many of these
growth factor-like actions are mediated by PAC1, the PACAP-
preferring receptor.
Growth factor-like actions of PACAP
PACAPhasbeenshowntoexhibit a variety oftrophic orgrowth
factor-like actions on cultured neurons and glia subtypes. Early
studies showed that PACAP stimulated the outgrowth of
neurites from PC12 cells (Deutsch and Sun, 1992). It was later
shown in cultured cortical precursor cells from E13 rats (E is
embryonic day) that PACAP induced cell cycle withdrawal and
promoted the transition from proliferation to differentiation
(Lu and DiCicco-Bloom, 1997). PACAP also potently increased
cAMP levels in cultured hindbrain neuroepithelial cells from
E10.5 mice and down-regulated the expression of the sonic
hedgehog-dependent target gene gli-1 (Waschek et al., 1998).
In other work, it was reported that PACAP increased mitosis in
cultured embryonic SCG (superior cervical ganglion) precursors
and potently enhanced precursor survival via the PACAP-
preferring PAC1 receptor (DiCicco-Bloom et al., 2000).
Furthermore, PACAP promoted SCG neuronal differentiation,
increased neurite outgrowth and enhanced expression of the
neurotrophin receptors trkC and trkA (DiCicco-Bloom et al.,
2000). PACAP effects on SCG precursors were shown to be
mediated by PAC1, via increased intracellular second messen-
gers including cAMP and phosphatidylinositol as well as Ca
2+.
This findings in SCG cultures explained early studies dem-
onstrating that high concentrations of VIP stimulate mitosis,
promote neurite outgrowth and enhance survival of sympath-
etic neuroblasts in culture (Pincus et al., 1990).
PACAP has been reported to prevent PCD (programmed cell
death) in cultured CGCs (cerebellar granule cells; Villalba
et al., 1997; Vaudry et al., 2000), as well as apoptosis induced
by different neurotoxins such as ethanol (Vaudry et al., 2002b),
H2O2 and H2O2 during oxidative stress (Vaudry et al., 2002a),
and ceramides (Vaudry et al., 2003). Using PC12 cells, it was
shown that PACAP provided protection against cytotoxicity
of b-amyloid, a key factor in AD (Alzheimer’s disease; Onoue
et al., 2002a) and of human prion protein fragment 106–126
[PrP(106–126)] (Onoue et al., 2002b). In purified embryonic
rat cortical cultures, PACAP suppressed glutamate-induced
neuronal cell death in up to 50% of the cells compared with
control (Morio et al., 1996). Moreover, PACAP was shown to
protect cerebral cortical neurons from neuronal loss triggered
by gp120, the envelope glycoprotein from the HIV (Brenneman
et al., 2002). These in vitro data supported those per-
formed in vivo. For example, in the ischaemia-induced
PMCAO (permanent middle cerebral artery occlusion) model,
PACAP, administered to rats either before (Reglodi et al.,
2002) or after the occlusion (Reglodi et al., 2000), signifi-
cantly reduced the infarct size. Likewise, in a model of
Parkinson’s disease, PACAP treatment effectively protected
the dopaminergic nigrostriatal neurons from apoptotic
death, and resulted in reduced neurological deficits and
more rapid amelioration of behavioural abnormalities
(Reglodi et al., 2004). Moreover, PACAP increased neuronal
survival after spinal cord compression (Chen and Tzeng, 2005),
suggesting that PACAP could have beneficial effects in tissue
restoration after nerve injury. Consistent with this hypothesis,
PACAP mRNA was up-regulated for as long as 30 days after
facial motor neuron axotomy (Zhou et al., 1999) and nerve
regeneration was impaired in PACAP KO animals (Armstrong
et al., 2008).
In most of the aforementioned studies, the effects of
PACAP were mediated through PAC1 receptor and linked to
the PKA pathway (Morio et al., 1996; Onoue et al., 2002b; Vaudry
et al., 2002a, 2003). However, it is clear that neuroprotective
actions include, but are not limited to, cAMP-mediated processes.
Thus, MAPK pathways also contribute to the neuroprotective
action of PACAP (Onoue et al., 2002b; Vaudry et al., 2002a,
2003). Forexample, itwasindicated that underbrain ischaemic
stress, PACAP acted in neurons through the inhibition of JNK
(c-Jun N-terminal kinase)/SAPK (stress-activated protein kinase)
and p38 signalling pathways (Dohi et al., 2002). Furthermore,
this latter action was also accompanied by blockade of DNA
fragmentation and inhibition of caspase-3 activation, the key
enzyme of the apoptosis process (Vaudry et al., 2000, 2002a,
2003; Onoue et al., 2002a). The effect of PACAP was mimicked
by cAMP analogues, and abrogated by inhibitors of PKA and
PKC, which implies that the process of caspase-3 de-activation
may be mediated via both the AC/cAMP/PKA and PLC/IP3/DAG
(diacylglycerol)/PKC signalling pathways (Vaudry et al., 2000;
Onoue et al., 2002a). It was observed that PACAP, in addition to
direct stimulation of neurons, can also affect them indirectly.
For example, in the ischaemic region, the peptide stimulated
astrocytes that secrete IL-6 into the cerebrospinal fluid. IL-6,
similar to PACAP, inhibited the activation of JNK/SAPK in
neuronal cells (Shioda et al., 1998). Finally, it has been suggested
that PACAP protects neurons from death after ischaemia
through induction of IL-6 and consequent activation of the
STAT3 and ERK (extracellular-signal-regulated kinase) signalling
pathways (Ohtaki et al., 2006).
Growth factor-like actions of PACAP are reviewed in Dejda
et al. (2005) and Shioda et al. (2006).
Growth factor-like actions of VIP
Well before the discovery of PACAP in 1989, the first report
of VIP neuroprotection appeared, showing that subnanomolar
concentrations of VIP rescued neurons in primary embryonic
spinal cord cultures deprived of electrical activity (Brenneman
et al., 1985; Brenneman and Eiden, 1986). Later, it was
reported that VIP provides neuronal defence by inducing
the synthesis and secretion of diverse neuroprotective glia-
derived trophic substances such as nerve growth factor (Hill
et al., 2002), cytokines (Brenneman et al., 2003), chemokines
(Brenneman et al., 2000a), protease nexin-1 (Festoff et al.,
1996) and particularly ADNF (activity-dependent neurotrophic
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dependent neuroprotective protein; Sigalov et al., 2000). ADNF
is reported to be a potent neuroprotective astroglia-derived
factor (Brenneman et al., 1996). Two fragments of ADNF,
ADNF-14 and ADNF-9, prevented cell death induced by gp120
(HIV envelope protein), b-amyloid (fragment 25–35) and
activation of glutamate NMDA (N-methyl-D-aspartate) type
receptors, being effective at femtomolar concentrations
(Brenneman et al., 1996, 1998, 1999, 2000b). Moreover, ADNF-9
was reported to exhibit greater potency and efficacy in
preventing cell death than ADNF-14 or the parent protein
ADNF (Brenneman et al., 1996, 2000b). In addition, experi-
mental data showed that ADNP mRNA concentration in the rat
astrocytes was increased 2–3-fold after a short exposure to VIP
(Bassan et al., 1999; Gozes et al., 2003). In cerebral cortical
cultures exposed to TTX (tetrodotoxin), gp120, b-amyloid or
NMDA, NAP (neutrophil-activating protein), an 8-amino acid
fragment ofADNP,exhibitedstrongerneuroprotectiveefficacy
than ADNF-9 itself (Gozes et al., 2003).
In vivo studies have corroborated the in vitro actions
of ADNF-9 and NAP described as follows: (i) ADNF-9 has
been shown to protect against gp120 in a model mimicking
intrauterine growth retardation which is common in infants
born to HIV-positive mothers (Dibbern et al., 1997) and
(ii) NAP improved the developmental reflexes and prevented
short-term memory deficits in a model of ApoE (apolipopro-
tein E)-deficient mice for AD (Bassan et al., 1999). Other
investigations have demonstrated that ADNF-9 may act as
an endogenous growth-regulating factor during embryonic
development (Hill et al., 1999). NAP and ADNF-9 prevented
cellular oxidative stress in a mouse model of fetal alcohol
syndrome where pregnant mice were exposed to ethanol
during mid-gestation (E8) (Spong et al., 2001). Finally, in the
PMCAO model, NAP provided a significant protection against
neuronal damage associated with stroke by inhibiting key
factors inducing apoptosis of neuronal cells (Leker et al., 2002).
In other studies, VIP was shown to inhibit pro-inflammatory
mediators released by activated microglia, which purportedly
contribute to the neuronal cell death in neurodegenerative
disorders. VIP also significantly blocked the microglia activa-
tion and production of neurotoxic factors including TNFa,I L - 1 b
and NO (nitric oxide) in a model of Parkinson’s disease and
brain trauma (Delgado and Ganea, 2003a, 2003b). Recently, it
has been demonstrated that VIP has a unique and potent
neuroprotective action of the perinatal white matter against
excitotoxicinsultsthat isnotrecapitulated byPACAP(Gressens
et al., 1998). Moreover, when given systemically, VIP and stable
VIP agonists appeared to promote axonal regrowth in this
model through VPAC2 receptors and PKC and MAPK pathways
(Passemard et al., 2011). On the other hand, VIP cytoprotective
effects in some contexts have been attributed to action on the
PAC1, specifically on the Hop2 splice variant of PAC1 (Pilzer
and Gozes, 2006). For example, the Hop2 splice variant has
been shown to be expressed and prevent toxicity during
oxidative stress (Pilzer and Gozes, 2006) and ischaemic injury
(Shioda et al., 2006).
Growth factor-like actions of VIP are reviewed in Waschek
(1995) and Dejda et al. (2005).
Taken together, interestingly, unlike the most current and
emerging therapeutic agents designed for the treatment of
MS, the therapeutic mechanisms of VIP and PACAP peptides
are not only delimited to their remarkable anti-inflammatory
function but also to their potent growth factor-like and
specifically neuroprotective effects.
PHARMACOLOGY AND DRUG DESIGN
Based on the above observations, VIP, PACAP, and their
receptors are currently being considered as therapeutic targets
for MS and other chronic inflammatory disorders. However, a
major drawback with the use of native peptides in therapy
is their high sensitivity to protease degradation and ultimately
their bioavailability. Indeed, VIP is a 28-amino acid peptide that
undergoes rapid degradation in vivo with a tK of less than
1 min in the blood (Domschke et al., 1978). Moreover, the
38-residue isoform of PACAP displays a tK of less than 5 min in
isolated human plasma, whereas PACAP27 is relatively resistant
to degradation in vitro (Bourgault et al., 2008a). This
observation suggests that the 28–38 region is essential for
the degradation of PACAP (Bourgault et al., 2008a). To
circumvent this problem, recent data indicated that acetylation
of the N-terminal end of PACAP confers resistance to DPPIV
(dipeptidyl peptidase IV) (Bourgault et al., 2008a). Other
strategies have been developed to protect the peptide against
degradation by insertion of VIP into micelles or nanoparticles
(Fernandez-Montesinos et al., 2009; Onyuksel et al., 2009). A
second major obstacle that reduces the therapeutic use of VIP
and PACAP in humans is their relative ability to act on multiple
VIP and PACAP receptor subtypes, or when given at high doses
evenonotherclassBGPCRs(Laburtheetal.,2007;Vaudryetal.,
2009). These cross-interactions may result in peripheral side
effectsinducedbyVIPandPACAP(Laburtheetal.,2007;Vaudry
et al., 2009). Strategies to overcome these compromising con-
ditions include the development of specific and metabolically
stable ligands of VPAC1, VPAC2, and PAC1 receptors.
Regarding VPAC receptors, most of the structure–activity
relationship analyses so far have been carried out with
VIP and PACAP derivatives and have contributed to the
development of valuable pharmacological tools that discrim-
inate between VPAC1 and VPAC2 (Laburthe and Couvineau,
2002; Laburthe et al., 2007; Vaudry et al., 2009). For instance,
the PACAP (6–38) fragment exhibits a 15-fold higher affinity
for VPAC2 than for VPAC1 (Gourlet et al., 1995), whereas
PACAP (1–25) possesses a 66-fold higher affinity for VPAC1
than for VPAC2 (Gourlet et al., 1998). Thus, a complete alanine
scanning (Nicole et al., 2000; Igarashi et al., 2002a, 2002b) as
well as D-amino acid scanning of VIP (Igarashi et al., 2002a,
2002b) allowed the rationally design of selective, high affinity
VIP and PACAP receptors in multiple sclerosis
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205and metabolically stable analogues of VPAC receptors. The
most potent and specific peptide agonist for VPAC1 receptor
currently available is [Ala
11,22,28]-VIP (Nicole et al., 2000).
Moreover, two analogues ([Ala
2,8,9,11,19,22,24,25,27,28])VIP and
[Ala
2,8,9,11,19,24228]VIP) were found to have high selectivity for
hVPAC1 (Onoue et al., 2011). [Ala
2,8,9,16,19,24,25]VIP agonist
for VPAC2 was much more metabolically stable than VIP
(Onoue et al., 2011). With regard to antagonists, [Ac-His
1D-
-Phe
2,K
15R
16L
27]VIP(3–7)/GRF(8–27) (also called PG 97–269) is
a selective high-affinity antagonist of the VPAC1 receptor
(Gourlet et al., 1997a). Regarding the VPAC2 receptor, the
cyclic peptide analogue of VIP [Ac-Glu
8OCH3-Tyr
10Lys
12Nle
17-
Ala
19Asp
25Leu
26-Lys
27,28-VIP(cyclo 21–25)] or Ro 25–1392 is a
potent and selective agonist (Xia et al., 1997). Likewise, the VIP
analogue RO 25–1553, that possesses a C-terminally extended tail
and an a-helix-stabilizing lactam bridge between residues 21 and
25, behaves as a selective VPAC2 agonist (Bolin et al., 1995;
Gourlet et al., 1997b). In our opinion, there is still no highly
selective VPAC2 receptor antagonist because PG 99-465, a VIP
analogue that antagonizes VIP action on the VPAC2 receptor, has
significant agonist activity on human VPAC1 receptor (Moreno
et al., 2000). Together, these data suggest that the C-terminal
helical domains of PACAP and VIP are important for the binding
affinity towards VPAC2, whereas, conversely, VPAC1 seems
tolerant to deletion at the C terminus.
Regarding PAC1 receptors, as for VPAC receptors, an
extensive set of structure–activity relationship studies was
performed combining alanine scanning, directed mutagen-
esis, deletion and/or chimaerism analyses. Thus, numerous
PACAP analogues have been synthesized to identify the
molecular determinants responsible for the recognition and
activation of the receptors (Bourgault et al., 2009a). In 1991,
a natural 61-amino acid vasodilator polypeptide called
maxadilan was isolated from the salivary gland extracts
of the blood-feeding sand fly (Lerner et al., 1991). Later,
although there is a lack of primary sequence homology with
PACAP, maxadilan was definitively characterized as a potent
and highly selective agonist of PAC1 (Moro and Lerner, 1997;
Lerner et al., 2007). A shortened maxadilan synthetic
analogue, termed as M65, in which the amino acid sequence
25–41 was deleted, acts as a specific PAC1 antagonist (Uchida
et al., 1998; Moro et al., 1999; Lerner et al., 2007). As
previously reported, the N-terminal region of PACAP seems to
play a crucial role for the biological activity of the peptide
(Gourlet et al., 1991; Robberecht et al., 1992a; Bitar and Coy,
1993). Indeed, gradual deletion of the N-terminal residues of
PACAP38 showed that PACAP(6–38) is a potent antagonist
(Robberecht et al., 1992b). Moreover, the chemical modification
of PACAP38 led to the development of [R
15, 20, 21,L
17]-PACAP38
which exhibited enhanced stability with a 42% reduction in
degradation kinetics compared with that of PACAP38 and
biological activity (Onoue et al., 2011). As discussed, PACAP27
and VIP possess a high degree of sequence homology (68%).
However, VIP is not able to bind to PAC1 efficiently. Because
sequence differences between VIP and PACAP are restricted to
regions 4–13 and 24–28, the PAC1 selectivity should reside
within these two regions. Synthesis and pharmacological
characterization of VIP/PACAP chimaeras showed that the
selectivity of PAC1 towards PACAP implicates not the C-terminal
domain but rather the chemical motifs of the 4–13 region
(Schafer et al., 1999; Onoue et al., 2001).
Although a multitude selective peptide agonists and, to a
lesser extent, antagonists have already been described, the
development of potent small non-peptide molecules acting
on VIP/PACAP receptors is a challenging goal. Indeed, the
hydrazides have been discovered recently as specific ant-
agonist for PAC1 receptor, and are the first potent small
molecule antagonists ever reported for VIP/PACAP receptors
(Beebe et al., 2008). In parallel, the recent finding of N-cap
motifs which orientate the N-terminal part of members of
VIP/secretin family, and are presumably involved in receptor
activation, may serve as a template for a new rational drug
design. Thus, the further structural analyses and structure–
activity relationship studies of the receptors should be very
helpful to understand the mechanism of activation of the
VIP/PACAP receptors, and ultimately for the design of new
non-peptide drugs targeting VIP and PACAP receptors.
CONCLUSION
Current and emerging therapeutic agents have so far been
primarily designed to suppress the immune response in MS
patients. They are capable of reducing the severity of early
stage MS and slowing its progression, but without having
significant action during the secondary phase of the disorder.
Thus, it is important to find new promising therapeutic tools
acting also on the neurodegenerative aspect of MS
physiopathology. VIP and PACAP exhibit not only a potent
anti-inflammatory action, but also remarkable neurotrophic
and neuroprotective actions. These peptides and their
receptors may modulate both the excess of inflammation
and the neurodegenerative processes associated with MS.
Recently, the development of VIP and PACAP-related drugs
in the treatment of multiple sclerosis has become a new
challenge.
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